Real world evidence provides clinical insights on tissue agnostic approvals of therapies


George Sledge, Takayuki Yoshino, Joanne Xiu, Anthony Helmstetter, Sergey Klimov, Brady Gilg, Matthew Oberley, Milan Radovich, Jim Abraham, David Spetzler


  • TA indications are common, with one patient in every five tested being a candidate for TA therapy; however, TA frequency varies tremendously across cancer types.
  • Response durations (as measured by TOT) may not be tissue agnostic.
  • Some TA approvals (e.g., TMB-H) extend beyond the initial study populations. RWE may extend TA indications to other drugs in the same class.
Download Publication